Lumida
/CSTL
⌘K
Castle Biosciences Inc

Castle Biosciences Inc

CSTL
$32.65USD-2.30%-0.77 today

MARKET CAP

997.4M

P/E (TTM)

FWD P/E

DAY RANGE

$32 – $34

52W RANGE

$18
$44

AI Summary

Stalk
Buy NowMedium

CSTL remains in a Stage 2 advancing regime with intermediate uptrend intact. After a run into overbought territory near $35, price has retraced into the rising 9- and 20-day EMAs and is holding the $31.70–$33.20 support zone. This shallow pullback offers a tactical entry aligned with the Speculative strategy’s preference for continuation on momentum-based setups. Immediate participation on this support test targets the recent highs and beyond.

  • Q2 revenue reached $103.5M, +20% YoY driven by core tests
  • TissueCypher volumes rose 63% YoY to 14,988 reports
  • Net loss of $2.1M in Q2 2026 amid rising SG&A costs
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$94.1M$137.0M$219.8M$332.1M$344.2M
YoY %+50.2%+45.7%+60.4%+51.1%+3.7%
P / Sales11.5x4.3x2.7x2.3x3.3x
EV / Sales8.5x3.8x2.5x2.2x3.2x
Gross Profit, Adj.$78.3M$105.0M$174.8M$271.9M$273.2M
YoY %+47.8%+34.2%+66.4%+55.5%+0.5%
Margin %83.2%76.6%79.5%81.9%79.4%
EV / Gross Profit10.2x4.9x3.2x2.7x4.1x
EBITDA, Adj.$-36.7M$-80.6M$-55.6M$24.7M$-2.0M
YoY %-504.2%-119.8%+31.0%+144.3%-108.3%
Margin %-39.0%-58.8%-25.3%7.4%-0.6%
EV / EBITDA-21.8x-6.4x-9.9x29.8x-548.6x
EBIT$-40.1M$-72.9M$-68.0M$8.7M$-42.8M
YoY %-512.6%-81.8%+6.7%+112.8%-593.8%
Margin %-42.6%-53.2%-30.9%2.6%-12.4%
EV / EBIT-19.9x-7.1x-8.1x84.8x-26.1x
Net Income$-31.3M$-67.1M$-57.5M$18.2M$-24.2M
YoY %-204.3%-114.6%+14.4%+131.7%-232.4%
Net Margin-33.3%-49.0%-26.1%5.5%-7.0%
EPS (GAAP)-$1.24-$2.58-$2.14$0.62-$0.83
YoY %-129.6%-108.1%+17.1%+129.0%-233.9%